EUVIMEDEUVIMED entdecken
Crossref

Antiviral Drugs for COVID-19 in Vaccinated Outpatients

The Medical Letter on Drugs and Therapeutics · 2023

DOI: 10.58347/tml.2023.1671a ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Medical Letter on Drugs and Therapeutics, 2023. Hauptthemen laut MEDLINE: Antiviral Agents, COVID-19.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Three products are currently available in the US for treatment of high-risk (see Table 1),1 nonhospitalized adults with mild to moderate COVID-19: oral ritonavir-boosted nirmatrelvir (Paxlovid), IV remdesivir (Veklury), and oral molnupiravir (Lagevrio). Remdesivir is FDA-approved for such use; nirmatrelvir/ritonavir and molnupiravir are available under an FDA Emergency Use Authorization. Because the pivotal clinical trials of these products for outpatient use were conducted in patients who were not vaccinated against COVID-19, some clinicians have questioned whether they can benefit vaccinated outpatients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsCOVID-19HumansOutpatients

Stichwörter der Autor:innen

COVID-19LagevrioPaxlovidVekluryantiviral drugsdosageefficacymolnupiravirnirmatrelvirremdesivirritonavirsafety

Substanzen

Antiviral Agents

Zitieren

APA

(2023). Antiviral Drugs for COVID-19 in Vaccinated Outpatients. The Medical Letter on Drugs and Therapeutics. https://doi.org/10.58347/tml.2023.1671a

Vancouver

Antiviral Drugs for COVID-19 in Vaccinated Outpatients. The Medical Letter on Drugs and Therapeutics. 2023. doi:10.58347/tml.2023.1671a

BibTeX
@article{euvimed2023,
  title = {Antiviral Drugs for COVID-19 in Vaccinated Outpatients},
  journal = {The Medical Letter on Drugs and Therapeutics},
  year = {2023},
  doi = {10.58347/tml.2023.1671a}
}
Kostenlos starten →